![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » OSCIENT PHARMACEUTICALS AND PFIZER, S.A. DE C.V. ANNOUNCE LAUNCH OF FACTIVE TABLETS IN MEXICO
OSCIENT PHARMACEUTICALS AND PFIZER, S.A. DE C.V. ANNOUNCE LAUNCH OF FACTIVE TABLETS IN MEXICO
FACTIVE (gemifloxacin mesylate) tablets, Oscient Pharmaceuticals Corporation's lead antibiotic product, has been launched by Pfizer, S.A. de C.V. (Pfizer Mexico), the largest pharmaceutical company in Mexico. Pfizer Mexico is promoting FACTIVE-5 in Mexico for the five-day treatment of acute bacterial exacerbations of chronic bronchitis (AECB), acute bacterial sinusitis (ABS) and community-acquired pneumonia (CAP).
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct